Loading...

Genus

DB:GBE
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GBE
DB
£1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
GBE Share Price and Events
7 Day Returns
-0.9%
DB:GBE
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-9%
DB:GBE
-5.6%
DE Biotechs
-4.5%
DE Market
GBE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genus (GBE) -0.9% -0.2% 2.3% -9% 34.6% 109.1%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • GBE underperformed the Biotechs industry which returned -5.6% over the past year.
  • GBE underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
GBE
Industry
5yr Volatility vs Market

Value

 Is Genus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Genus to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Genus.

DB:GBE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GBE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 19%) (7.45%))
1.362
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.36
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.362 * 6.65%)
9.29%

Discounted Cash Flow Calculation for DB:GBE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Genus is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:GBE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 9.29%)
2019 10.51 Analyst x3 9.61
2020 21.42 Analyst x3 17.94
2021 25.50 Analyst x3 19.54
2022 38.70 Analyst x1 27.13
2023 48.72 Est @ 25.89% 31.25
2024 57.58 Est @ 18.19% 33.80
2025 64.95 Est @ 12.8% 34.88
2026 70.82 Est @ 9.03% 34.80
2027 75.34 Est @ 6.39% 33.88
2028 78.76 Est @ 4.54% 32.41
Present value of next 10 years cash flows £275.24
DB:GBE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £78.76 × (1 + 0.23%) ÷ (9.29% – 0.23%)
£871.47
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £871.47 ÷ (1 + 9.29%)10
£358.58
DB:GBE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £275.24 + £358.58
£633.82
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £633.82 / 64.47
£9.83
DB:GBE Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GBE represents 1.15766x of LSE:GNS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.15766x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 9.83 x 1.15766
€11.38
Value per share (EUR) From above. €11.38
Current discount Discount to share price of €26.58
= -1 x (€26.58 - €11.38) / €11.38
-133.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Genus is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GBE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in GBP £-0.11
LSE:GNS Share Price ** LSE (2019-04-25) in GBP £22.96
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genus.

DB:GBE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:GNS Share Price ÷ EPS (both in GBP)

= 22.96 ÷ -0.11

-213.89x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genus is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Genus is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Genus's expected growth come at a high price?
Raw Data
DB:GBE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -213.89x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
27.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genus, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genus's assets?
Raw Data
DB:GBE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in GBP £7.89
LSE:GNS Share Price * LSE (2019-04-25) in GBP £22.96
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:GBE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:GNS Share Price ÷ Book Value per Share (both in GBP)

= 22.96 ÷ 7.89

2.91x

* Primary Listing of Genus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genus is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Genus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Genus has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Genus expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genus expected to grow at an attractive rate?
  • Genus's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Genus's earnings growth is expected to exceed the Germany market average.
  • Genus's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GBE Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GBE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 27.5%
DB:GBE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 4.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GBE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GBE Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 573 1
2022-06-30 561 69 46 2
2021-06-30 547 54 49 5
2020-06-30 516 48 44 5
2019-06-30 488 37 47 5
DB:GBE Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-12-31 471 37 -7
2018-09-30 470 40 18
2018-06-30 470 43 43
2018-03-31 473 42 55
2017-12-31 476 41 67
2017-09-30 467 38 50
2017-06-30 459 35 33
2017-03-31 441 34 40
2016-12-31 422 33 47
2016-09-30 405 31 48
2016-06-30 388 30 49
2016-03-31 388 25 40

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genus's earnings are expected to grow significantly at over 20% yearly.
  • Genus's revenue is expected to grow by 4.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GBE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Genus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GBE Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30
2022-06-30 0.70 0.70 0.70 1.00
2021-06-30 0.73 0.85 0.62 3.00
2020-06-30 0.65 0.79 0.55 3.00
2019-06-30 0.74 0.74 0.74 1.00
DB:GBE Past Financials Data
Date (Data in GBP Millions) EPS *
2018-12-31 -0.11
2018-09-30 0.29
2018-06-30 0.70
2018-03-31 0.90
2017-12-31 1.09
2017-09-30 0.82
2017-06-30 0.54
2017-03-31 0.65
2016-12-31 0.77
2016-09-30 0.79
2016-06-30 0.81
2016-03-31 0.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Genus is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Genus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genus has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Genus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genus's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genus does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Genus's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genus's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Genus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GBE Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 470.50 -6.60 81.00 51.40
2018-09-30 470.40 18.05 81.30 51.40
2018-06-30 470.30 42.70 81.60 51.40
2018-03-31 472.95 54.75 80.35 48.40
2017-12-31 475.60 66.80 79.10 45.40
2017-09-30 467.35 49.80 78.50 45.40
2017-06-30 459.10 32.80 77.90 45.40
2017-03-31 440.60 39.80 74.65 39.90
2016-12-31 422.10 46.80 71.40 34.40
2016-09-30 405.20 48.05 71.25 34.40
2016-06-30 388.30 49.30 71.10 34.40
2016-03-31 388.30 39.90 67.75 31.50
2015-12-31 388.30 30.50 64.40 28.60
2015-09-30 393.40 35.20 64.35 28.60
2015-06-30 398.50 39.90 64.30 28.60
2015-03-31 393.75 35.80 60.35 28.15
2014-12-31 389.00 31.70 56.40 27.70
2014-09-30 380.60 30.30 56.95 27.70
2014-06-30 372.20 28.90 57.50 27.70
2014-03-31 366.00 27.05 58.70 27.85
2013-12-31 359.80 25.20 59.90 28.00
2013-09-30 352.55 24.30 59.80 28.00
2013-06-30 345.30 23.40 59.70 28.00
2013-03-31 343.70 30.10 55.30 26.55
2012-12-31 342.10 36.80 50.90 25.10
2012-09-30 341.95 38.15 50.20 25.10
2012-06-30 341.80 39.50 49.50 25.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Genus has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Genus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genus has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Genus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genus's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Genus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genus Company Filings, last reported 3 months ago.

DB:GBE Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 488.40 110.30 25.00
2018-09-30 488.40 110.30 25.00
2018-06-30 419.10 137.60 31.60
2018-03-31 419.10 137.60 31.60
2017-12-31 423.20 141.10 27.70
2017-09-30 423.20 141.10 27.70
2017-06-30 402.10 138.10 26.50
2017-03-31 402.10 138.10 26.50
2016-12-31 396.00 146.40 37.00
2016-09-30 396.00 146.40 37.00
2016-06-30 368.10 124.90 34.00
2016-03-31 368.10 124.90 34.00
2015-12-31 313.00 115.20 27.00
2015-09-30 313.00 115.20 27.00
2015-06-30 305.10 93.20 21.30
2015-03-31 305.10 93.20 21.30
2014-12-31 295.50 97.00 23.80
2014-09-30 295.50 97.00 23.80
2014-06-30 285.30 86.90 22.80
2014-03-31 285.30 86.90 22.80
2013-12-31 287.30 100.60 20.70
2013-09-30 287.30 100.60 20.70
2013-06-30 300.50 71.30 18.40
2013-03-31 300.50 71.30 18.40
2012-12-31 274.20 75.30 11.40
2012-09-30 274.20 75.30 11.40
2012-06-30 278.00 75.00 18.60
  • Genus's level of debt (22.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (35% vs 22.6% today).
  • Debt is well covered by operating cash flow (33.9%, greater than 20% of total debt).
  • Genus is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Genus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genus has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Genus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.13%
Current annual income from Genus dividends. Estimated to be 1.34% next year.
If you bought €2,000 of Genus shares you are expected to receive €23 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Genus's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.44%).
  • Genus's dividend is below the markets top 25% of dividend payers in Germany (3.67%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GBE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GBE Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30 0.35 2.00
2021-06-30 0.33 5.00
2020-06-30 0.30 5.00
2019-06-30 0.28 5.00
DB:GBE Past Annualized Dividends Data
Date (Data in £) Dividend per share (annual) Avg. Yield (%)
2018-11-15 0.260 1.148
2017-10-12 0.236 0.965
2017-09-07 0.236 1.136
2017-02-23 0.221 1.232
2016-09-08 0.214 1.154
2016-09-07 0.214 1.108
2015-11-19 0.195 1.258
2014-10-13 0.177 1.304
2013-09-03 0.161 1.383
2013-02-25 0.151 1.064
2012-10-09 0.146 1.032
2012-09-04 0.146 1.016
2012-02-21 0.090 0.699
2011-10-11 0.133 1.283
2011-09-06 0.133 1.305
2010-10-11 0.121 1.326
2010-09-07 0.121 1.553
2009-10-09 0.110 1.586
2009-09-10 0.110 1.589

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Genus's earnings are paid to the shareholders as a dividend.
  • The company is paying a dividend however it is incurring a loss.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.6x coverage).
X
Income/ dividend checks
We assess Genus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genus has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Genus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Karim Bitar
COMPENSATION £2,540,000
AGE 53
TENURE AS CEO 7.6 years
CEO Bio

Mr. Karim Bitar has been the Chief Executive Officer of Genus plc since September 30, 2011. Mr. Bitar has been an Executive Director of Genus plc since September 1, 2011. He is responsible for devising and implementing Genus' strategy and for managing its day-to-day operations. He is accountable to the Board for Genus' development, in line with its strategy, taking into account the risks, objectives and policies set out by the Board and its Committees. He has extensive experience of leading international, technology-focused organisations. He led the strategic review of Genus in 2012, resulting in a new vision, strategy, structure and core values. He served for more than 15 years at Eli Lilly and Company including as the President of European Operations since July 2008 and Lilly Canada and Lilly Australia. He held a variety of international roles, including, General Manager of Lilly Italy. He is an ex-McKinsey and Company consultant, he also held management roles at Johnson and Johnson and the Dow Chemical Company. He has been a Non Executive Director of Spectris plc since July 01, 2017. He has been a member of the University of Michigan Ross School of Business Advisory Board. He has a BSc in Biochemistry from the University of Wisconsin and an MBA from the University of Michigan.

CEO Compensation
  • Karim's compensation has been consistent with company performance over the past year.
  • Karim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Genus management team in years:

6.1
Average Tenure
  • The average tenure for the Genus management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Karim Bitar

TITLE
CEO & Executive Director
COMPENSATION
£3M
AGE
53
TENURE
7.6 yrs

Steven Wilson

TITLE
Group Finance Director & Executive Director
COMPENSATION
£2M
AGE
58
TENURE
6.1 yrs

Jonathan Lightner

TITLE
Chief of R&D and Scientific Officer

Dan Hartley

TITLE
Group General Counsel & Company Secretary
TENURE
4.8 yrs

Angelle Rosata

TITLE
Group Human Resources Director
TENURE
1.8 yrs

Bill Christianson

TITLE
Chief Operating Officer of Genus PIC
TENURE
9.2 yrs

Jerry Thompson

TITLE
Chief Operating Officer of Genus ABS Beef
TENURE
6.8 yrs

Nate Zwald

TITLE
Chief Operating Officer of Genus ABS Dairy
TENURE
2.2 yrs

Cara Crichton

TITLE
Deputy Company Secretary
Board of Directors Tenure

Average tenure and age of the Genus board of directors in years:

3
Average Tenure
64
Average Age
  • The tenure for the Genus board of directors is about average.
Board of Directors

Bob Lawson

TITLE
Non-Executive Chairman
COMPENSATION
£162K
AGE
73
TENURE
8.4 yrs

Lykele van der Broek

TITLE
Non-Executive Director & Chairman of the Supervisory Board
COMPENSATION
£56K
AGE
64
TENURE
0.4 yrs

Karim Bitar

TITLE
CEO & Executive Director
COMPENSATION
£3M
AGE
53
TENURE
7.6 yrs

Steven Wilson

TITLE
Group Finance Director & Executive Director
COMPENSATION
£2M
AGE
58
TENURE
6.3 yrs

Lysanne Gray

TITLE
Non-Executive Director
COMPENSATION
£61K
TENURE
3 yrs

Lesley Mary Knox

TITLE
Senior Independent Non-Executive Director
COMPENSATION
£5K
AGE
65
TENURE
0.4 yrs

Ian Charles

TITLE
Non-Executive Director
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Sep 18 Sell Jonathan Lightner Individual 14. Sep 18 14. Sep 18 -1,301 €28.10 €-36,564
18. May 18 Sell William Christianson Individual 17. May 18 17. May 18 -30,000 €29.54 €-886,328
X
Management checks
We assess Genus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos, which are delivered through artificial insemination to breed dairy and beef cattle with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers; and agricultural and agri-food consultancy services. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom.

Details
Name: Genus plc
GBE
Exchange: DB
Founded: 1994
£1,714,900,948
64,467,202
Website: http://www.genusplc.com
Address: Genus plc
Matrix House,
Basing View,
Basingstoke,
Hampshire, RG21 4DZ,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE GNS Ordinary Shares London Stock Exchange GB GBP 30. Jan 1998
OTCPK GENS.F Ordinary Shares Pink Sheets LLC US USD 30. Jan 1998
DB GBE Ordinary Shares Deutsche Boerse AG DE EUR 30. Jan 1998
BATS-CHIXE GNSL Ordinary Shares BATS 'Chi-X Europe' GB GBP 30. Jan 1998
Number of employees
Current staff
Staff numbers
2,900
Genus employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 21:59
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.